In vivo mitochondrial and glycolytic impairments in patients with Alzheimer disease.

OBJECTIVE

In vivo glycolysis-related glucose metabolism and electron transport chain-related mitochondrial activity may be different regionally in the brains of patients with Alzheimer disease (AD). To test this hypothesis regarding AD pathophysiology, we measured the availability of mitochondrial complex-I (MC-I) with the novel PET probe [F]2-tert- butyl-4-chloro-5-2H- pyridazin-3-one ([F]BCPP-EF), which binds to MC-I, and compared [F]BCPP-EF uptake with F-fluorodeoxyglucose ([F]FDG) uptake in the living AD brain.

METHODS

First, the total distribution volume (V) of [F]BCPP-EF from 10 normal controls (NCs) was quantified using arterial blood samples and then tested to observe whether V could substitute for the standard uptake value relative to the global count (SUVRg). Eighteen NCs and 14 different NCs underwent PET with [F]BCPP-EF or [F]FDG, respectively. Second, 32 patients with AD were scanned semiquantitatively with double PET tracers. Interparticipant and intraparticipant comparisons of the levels of MC-I activity ([F]BCPP-EF) and glucose metabolism ([F]FDG) were performed.

RESULTS

The [F]BCPP-EF V was positively correlated with the [F]BCPP-EF SUVRg, indicating that the use of the SUVRg was sufficient for semiquantitative evaluation. The [F]BCPP-EF SUVRg, but not the [F]FDG SUVRg, was significantly lower in the parahippocampus in patients with AD, highlighting the prominence of oxidative metabolic failure in the medial temporal cortex. Robust positive correlations between the [F]BCPP-EF SUVRg and [F]FDG SUVRg were observed in several brain regions, except the parahippocampus, in early-stage AD.

CONCLUSIONS

Mitochondrial dysfunction in the parahippocampus was shown in early-stage AD. Mitochondria-related energy failure may precede glycolysis-related hypometabolism in regions with pathologically confirmed early neurodegeneration in AD.